News – Page 959 – Endpoints News

Gottlieb testifies on status of FDA operations after government shutdown

7 years ago

Investor opposition to Bristol-Myers' $74B Celgene buyout grows as activist Starboard joins the rebellion

7 years ago

Michael Cohen on Novartis ties: '(T)hey wanted me to provide access to government, including the president'

7 years ago

China's CStone raises $285M in IPO; Axial raises $25M for microbiome work on Parkinson's, autism

7 years ago

Scientists hold out hope for regenerative infusion via brain implant — despite failing its first test in ...

7 years ago

Plotting to go toe-to-toe with heavyweight Pfizer, little Eidos plans quick score in PhIII ATTR-CM study

7 years ago

Sarepta posts early, rosy gene therapy data for limb girdle muscular dystrophy — fueling $165M buyout of partner

7 years ago

Novartis, AbbVie dominate the top 10 list of blockbusters prepping for a 2019 marketing launch

7 years ago

FDA hands back Adamis' application for an ED drug, looking for more data

7 years ago

Parexel recruits top FDA oncology expert Amy McKee for new R&D initiative

7 years ago

Blackstone antes $250M on its first big biotech bet, focused on a cardio drug spun out of Novartis

7 years ago

FDA experts turn thumbs down on Karyopharm’s troubled pitch for an accelerated OK — but not all of them

7 years ago

In landmark hearing, drugmakers and lawmakers agree that US policy on drug pricing is ripe for change — but there's ...

7 years ago

Amicus blueprints growth plans for Philly-based gene therapy group; Cash-strapped Compugen restructures, cuts 35 ...

7 years ago

Is the $74B Celgene buyout already forcing a reckoning among Bristol-Myers Squibb’s R&D partners?

7 years ago

Oyster Point investors bet $93M on a PhIII study aimed at disrupting a major consumer market and toppling Allergan

7 years ago

Cornell researchers to launch early trial of gene therapy aimed — ultimately — at preventing Alzheimer's

7 years ago

The Roche way: Spark found a new owner who wants to buy and build a gene therapy leader

7 years ago

Temasek leads $85M round for Chinese biotech aiming for cheaper, faster, better CAR-T therapies

7 years ago

Daiichi Sankyo shakes up its R&D leadership, dispatching Junichi Koga to the US to run global ops

7 years ago

AstraZeneca, Merck notch another major Lynparza trial win — this time in pancreatic cancer

7 years ago

Additional exclusivity for a cancer treatment could cost the public $3 billion, analyst says

7 years ago

Immunomedics CEO Michael Pehl hits the exit on the heels of a CRL and accusations of a data integrity breach

7 years ago

FDA sounds the alarm on Pfizer’s blockbuster Xeljanz after a high dose was linked to a higher death rate, blood ...

7 years ago

First page Previous page 956 957 958959960 961 962 Next page Last page